Reply to ‘Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents’ by Saad and Buyse


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles